Diurnal Group (DNL) Hits New 12-Month High at $147.00
Diurnal Group PLC (LON:DNL) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as GBX 147 ($1.97) and last traded at GBX 146.50 ($1.96), with a volume of 0 shares traded. The stock had previously closed at GBX 146.50 ($1.96).
Separately, Numis Securities reissued a “buy” rating and set a GBX 185 ($2.47) price target on shares of Diurnal Group in a research report on Monday, December 18th.
The company has a market capitalization of $87.09 and a P/E ratio of -813.89.
In related news, insider Martin Whitaker purchased 3,703 shares of the firm’s stock in a transaction dated Monday, November 27th. The stock was bought at an average price of GBX 135 ($1.81) per share, for a total transaction of £4,999.05 ($6,684.12).
About Diurnal Group
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.
Receive News & Ratings for Diurnal Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group and related companies with MarketBeat.com's FREE daily email newsletter.